Stay updated on LBR-101 in High Frequency Episodic Migraine Clinical Trial
Sign up to get notified when there's something new on the LBR-101 in High Frequency Episodic Migraine Clinical Trial page.

Latest updates to the LBR-101 in High Frequency Episodic Migraine Clinical Trial page
- Check3 days agoChange DetectedThe clinical trial record for LBR-101 (fremanezumab) is displayed, including its completed Phase 2 study design, eligibility criteria, outcomes, participating locations, and posted results and publications.SummaryDifference72%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe footer revision number changes from v3.7.2 to v3.8.0 while the 403 error page remains otherwise unchanged.SummaryDifference0.2%

- Check24 days agoChange DetectedA site-wide NIH notice announces a transition from using “Artificial Intelligence” to “Super Intelligence” in federal agency content, noting that both terms may appear during the transition.SummaryDifference1%

- Check31 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2 while the study page remains an error page.SummaryDifference0.2%

- Check38 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.0 to v3.7.1, while the study page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check52 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the full study record content with a 403 message and a Home link. This blocks access to the trial details and related information, indicating a page-level access restriction.SummaryDifference17%

Stay in the know with updates to LBR-101 in High Frequency Episodic Migraine Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LBR-101 in High Frequency Episodic Migraine Clinical Trial page.